Bank of New York Mellon Corp Acquires New Position in Illumina, Inc. $ILMN

Bank of New York Mellon Corp purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,671,192 shares of the life sciences company's stock, valued at approximately $293,846,000. Bank of New York Mellon Corp owned approximately 1.11% of Illumina at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Capital World Investors raised its stake in shares of Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company's stock worth $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp grew its position in shares of Illumina by 3.2% in the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company's stock valued at $811,895,000 after purchasing an additional 190,324 shares during the last quarter. WCM Investment Management LLC grew its position in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company's stock valued at $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company's stock worth $375,260,000 after purchasing an additional 130,139 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Insider Buying and Selling

In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares of the company's stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company's stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is owned by company insiders.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Barclays upped their target price on Illumina from $145.00 to $160.00 and gave the company an "underweight" rating in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft downgraded Illumina to a "hold" rating in a research report on Wednesday, August 5th. Zacks Research upgraded Illumina from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. increased their price objective on Illumina from $220.00 to $230.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. Finally, Wall Street Zen upgraded Illumina from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, Illumina has a consensus rating of "Hold" and an average target price of $188.40.

Illumina Stock Up 2.9%

ILMN stock opened at $219.40 on Friday. The stock has a market capitalization of $33.13 billion, a P/E ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a one year low of $88.00 and a one year high of $220.43. The company has a 50 day moving average price of $188.01 and a two-hundred day moving average price of $152.44.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the company posted $1.19 EPS. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source